Wockhardt in licensing pact with UK firm for acne drug
Wockhardt Ltd has signed an in-licensing agreement with Crawford Healthcare, UK to market Zindaclin, a patented topical application for acne.
By INDIATIMES NEWS NETWORK |
MUMBAI: Wockhardt Ltd has signed an in-licensing agreement with Crawford Healthcare, UK to market Zindaclin, a patented topical application for acne. Zindaclin is the first 'Once-a-day' acne antibiotic to be launched in India. According to ORG-IMS, the Indian market for this product is about Rs 168 crore.
"Zindaclin has proved its effectiveness in Europe and the US. This product will greatly benefit Indian patients with its efficacy and usage pattern,” said Chairman Habil Khorakiwala.
This licensing deal follows the launch of Vitix & Viticolor, patented products from LSI & Crawford of UK respectively, for the treatment of Vitiligo in the Indian market.
As in the case of Vitix & Viticolor, Wockhardt will manufacture Zindaclin in India from imported active ingredients. Zindaclin will be launched in the fourth quarter of 2007 by Wockhardt's dedicated dermatology team, SkinUno.
"Zindaclin has proved its effectiveness in Europe and the US. This product will greatly benefit Indian patients with its efficacy and usage pattern,” said Chairman Habil Khorakiwala.
This licensing deal follows the launch of Vitix & Viticolor, patented products from LSI & Crawford of UK respectively, for the treatment of Vitiligo in the Indian market.
As in the case of Vitix & Viticolor, Wockhardt will manufacture Zindaclin in India from imported active ingredients. Zindaclin will be launched in the fourth quarter of 2007 by Wockhardt's dedicated dermatology team, SkinUno.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
